The Peptomyc technology and intellectual property are based on the expertise acquired by Dr. Soucek's laboratory regarding Omomyc, a potent Myc inhibitor with significant therapeutic potential across various cancer types. Initially viewed as a proof of concept and intended solely for gene therapy, it has been revealed that the Omomyc peptide itself possesses remarkable cell-penetrating capabilities, effectively entering cells and exhibiting strong anti-Myc activity, leading to the arrest or demise of cancer cells.